A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Conditions:   Ulcerative Colitis (UC);   Crohn's Disease Interventions:   Drug: Risankizumab;   Drug: Cytochrome P450 (CYP) Substrates Sponsor:   AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials